1
|
Jaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, Chaouat A, Cottin V, De Groote P, Favrolt N, Horeau-Langlard D, Magro P, Savale L, Prévot G, Renard S, Sitbon O, Parent F, Trésorier R, Tromeur C, Piedvache C, Grimaldi L, Fadel E, Montani D, Humbert M, Simonneau G. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. The Lancet Respiratory Medicine 2022; 10:961-971. [DOI: 10.1016/s2213-2600(22)00214-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Revised: 05/12/2022] [Accepted: 05/19/2022] [Indexed: 01/05/2023]
|
2
|
Benkalfate N, Eschapasse E, Georges T, Leblanc C, Dirou S, Melscoet L, Chéné AL, Horeau-Langlard D, Bry C, Chambellan A, Nicolas A, Claire D, Liberge R, Karakachoff M, Hardouin JB, Blanc FX, Lemarchand P. Evaluation of the Post-COVID-19 Functional Status (PCFS) Scale in a cohort of patients recovering from hypoxemic SARS-CoV-2 pneumonia. BMJ Open Respir Res 2022; 9:9/1/e001136. [PMID: 35264326 PMCID: PMC8915286 DOI: 10.1136/bmjresp-2021-001136] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Accepted: 02/17/2022] [Indexed: 11/05/2022] Open
Abstract
Introduction COVID-19 sequelae are numerous and multisystemic, and how to evaluate those symptomatic patients is a timely issue. Klok et al proposed the Post-COVID-19 Functional Status (PCFS) Scale as an easy tool to evaluate limitations related to persistent symptoms. Our aim was to analyse PCFS Scale ability to detect functional limitations and its correlation with quality of life in a cohort of patients, 2–9 months after hospitalisation for COVID-19 hypoxemic pneumonia. Methods PCFS Scale was evaluated in 121 patients together with quality of life and dyspnoea questionnaires, pulmonary function tests and CT scans. Results We observed a high correlation with multiple questionnaires (Short Form-36, Hospital Anxiety and Depression Scale, modified Medical Research Council, end Borg Six-Minute Walk Test), making the PCFS Scale a quick and global tool to evaluate functional limitations related to various persistent symptoms following COVID-19 pneumonia. Discussion The PCFS Scale seems to be a suitable instrument to screen for patients who will require careful follow-up after COVID-19 hypoxemic pneumonia even in the absence of pulmonary sequelae.
Collapse
Affiliation(s)
- Naïla Benkalfate
- Nantes University, CHU Nantes, Departement of Respiratory Medicine, l'institut du thorax, F-44000 Nantes, Pays de la Loire, France
| | - Emmanuel Eschapasse
- Nantes University, CHU Nantes, Departement of Respiratory Medicine, l'institut du thorax, F-44000 Nantes, Pays de la Loire, France
| | - Thomas Georges
- Nantes University, CHU Nantes, Departement of Respiratory Medicine, l'institut du thorax, F-44000 Nantes, Pays de la Loire, France
| | - Camille Leblanc
- Nantes University, CHU Nantes, Departement of Respiratory Medicine, l'institut du thorax, F-44000 Nantes, Pays de la Loire, France
| | - Stephanie Dirou
- Nantes University, CHU Nantes, Departement of Respiratory Medicine, l'institut du thorax, F-44000 Nantes, Pays de la Loire, France
| | - Lise Melscoet
- Nantes University, CHU Nantes, Departement of Respiratory Medicine, l'institut du thorax, F-44000 Nantes, Pays de la Loire, France
| | - Anne-Laure Chéné
- Nantes University, CHU Nantes, Departement of Respiratory Medicine, l'institut du thorax, F-44000 Nantes, Pays de la Loire, France
| | - Delphine Horeau-Langlard
- Nantes University, CHU Nantes, Departement of Respiratory Medicine, l'institut du thorax, F-44000 Nantes, Pays de la Loire, France
| | - Charlotte Bry
- Nantes University, CHU Nantes, Departement of Respiratory Medicine, l'institut du thorax, F-44000 Nantes, Pays de la Loire, France
| | - Arnaud Chambellan
- Nantes University, CHU Nantes, Department of Physiology, l'Institut du thorax, Laboratoire MIP, F-44000 Nantes, France
| | - Aymeric Nicolas
- Nantes University, CHU Nantes, Department of Radiology, F-44000 Nantes, France
| | - Defrance Claire
- Nantes University, CHU Nantes, Department of Radiology, F-44000 Nantes, France
| | - Renan Liberge
- Nantes University, CHU Nantes, Department of Radiology, F-44000 Nantes, France
| | - Matilde Karakachoff
- Nantes University, CHU Nantes, INSERM, Clinique des données, CIC 1413, F-44000 Nantes, France
| | - Jean-Benoit Hardouin
- Nantes Université, Univ Tours, CHU Nantes, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000 Nantes, France
| | - François-Xavier Blanc
- Nantes University, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France
| | - Patricia Lemarchand
- Nantes University, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France
| |
Collapse
|
3
|
Delbove A, Senage T, Gazengel P, Tissot A, Lacoste P, Cellerin L, Perigaud C, Danner-Boucher I, Cavailles A, Lepoivre T, Mugniot A, Nicolet J, Horeau-Langlard D, Groleau N, Fedun Y, Rozec B, Magnan A, Roussel JC, Blanc FX. Incidence and risk factors of anastomotic complications after lung transplantation. Ther Adv Respir Dis 2022; 16:17534666221110354. [PMID: 35894432 PMCID: PMC9340386 DOI: 10.1177/17534666221110354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background: Anastomotic complications are common after lung transplantation (1.4–33% of
cases) and still associated with a high morbi-mortality. Methods: The current study is a monocenter retrospective analysis of symptomatic
anastomotic complications (SAC) occurring after lung transplantation between
2010 and 2016, using the macroscopic, diameter, and suture (M-D-S)
classification from consensus of French experts in bronchoscopy. The
objectives were to determine incidence from surgery, risk factors, and
impact of survival of SAC. We defined SAC as M-D-S abnormalities
(stenosis ⩾ 50% or dehiscence) requiring bronchoscopic or surgical
interventions. Results: A total of 121 patients were included. SAC occurred in 26.5% of patients
(n = 32), divided in symptomatic stenosis for 23.7%
(n = 29), and symptomatic dehiscence in 2.5%
(n = 3). In multivariate analysis, donor bacterial lung
infection [HR 2.08 (1.04–4.17), p = 0.04] and age above
50 years [HR 3.26 (1.04–10.26), p = 0.04] were associated
with SAC occurrence. Cystic fibrosis etiology was associated with better
survival on Kaplan–Meier curve (p < 0.001). SAC [HR 2.15
(1.07–4.32), p = 0.03] was independently associated with
worst survival. The 29 symptomatic patients because of stenosis required
endoscopic procedure, of whom 16 patients needed bronchial stent placement.
Four patients underwent surgery: three patients because of dehiscence and
one because of severe bilateral stenosis (re-transplantation). Discussion: SAC occurred in 26.5% of patients. Donor lung infection was the only
alterable identified factors. The increase rate of SAC in older patients
above 50 years of age encourages in regular endoscopic monitoring.
Collapse
Affiliation(s)
- Agathe Delbove
- Service de Pneumologie, L'institut du thorax, Boulevard Jacques Monod, CHU Nantes, hôpital G. et R. Laennec, 44 093 Nantes cedex 1, France.,Current address: Service de Réanimation polyvalente, Centre Hospitalier Bretagne Atlantique, 20, Boulevard du Général Maurice Guillaudot, 56 017 Vannes Cedex, France
| | - Thomas Senage
- Service de chirurgie thoracique et cardiovasculaire, CHU Nantes, Nantes, France.,INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France
| | - Pierre Gazengel
- Service de pneumologie, l'institut du thorax, CHU Nantes, Nantes, France.,Service de transplantation, Clinique chirurgicale Marie Lannelongue, Le Plessis Robinson, France
| | - Adrien Tissot
- Service de pneumologie, l'institut du thorax, CHU Nantes, Nantes, France
| | - Philippe Lacoste
- Service de chirurgie thoracique et cardiovasculaire, CHU Nantes, Nantes, France
| | - Laurent Cellerin
- Service de pneumologie, l'institut du thorax, CHU Nantes, Nantes, France
| | - Christian Perigaud
- Service de chirurgie thoracique et cardiovasculaire, CHU Nantes, Nantes, France
| | | | - Arnaud Cavailles
- Service de pneumologie, l'institut du thorax, CHU Nantes, Nantes, France
| | - Thierry Lepoivre
- INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France
| | - Antoine Mugniot
- Service de chirurgie thoracique et cardiovasculaire, CHU Nantes, Nantes, France
| | - Johanna Nicolet
- Service de réanimation chirurgicale thoracique et cardiovasculaire, CHU Nantes, Nantes, France
| | | | - Nicolas Groleau
- Service de réanimation chirurgicale thoracique et cardiovasculaire, CHU Nantes, Nantes, France
| | - Yannick Fedun
- Service de réanimation polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France
| | - Bertrand Rozec
- Service de réanimation chirurgicale thoracique et cardiovasculaire, CHU Nantes, Nantes, France
| | - Antoine Magnan
- Service de pneumologie, l'institut du thorax, CHU Nantes, Nantes, France.,Service de Pneumologie, Hôpital Foch, Suresnes, France
| | | | | |
Collapse
|
4
|
Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, Chaouat A, Picard F, Horeau-Langlard D, Bourdin A, Jutant EM, Beurnier A, Jevnikar M, Jaïs X, Simonneau G, Montani D, Sitbon O, Humbert M. External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. Eur Respir J 2021; 59:13993003.02419-2021. [PMID: 34737227 PMCID: PMC9245192 DOI: 10.1183/13993003.02419-2021] [Citation(s) in RCA: 64] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2021] [Accepted: 10/28/2021] [Indexed: 11/05/2022]
Abstract
Introduction Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators. Methods We evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan–Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches. Results At baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk. Conclusions The four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach. A four-stratum risk assessment method with low, intermediate-low, intermediate-high and high risk categories was better at discriminating survival in pulmonary arterial hypertension than a three-stratum method with low, intermediate and high risk groupshttps://bit.ly/3mA6kj7
Collapse
Affiliation(s)
- Athénaïs Boucly
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Both authors contributed equally
| | - Jason Weatherald
- Department of Medicine, Division of Respirology, and Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.,Both authors contributed equally
| | - Laurent Savale
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Pascal de Groote
- Université de Lille, Service de cardiologie, CHU Lille, Institut Pasteur de Lille, Inserm U1167, Lille, France
| | - Vincent Cottin
- Université Lyon 1, INRAE, UMR754, IVPC, National Reference Centre for Rare Pulmonary Diseases, Hospices Civils de Lyon, Lyon, France
| | - Grégoire Prévot
- CHU de Toulouse, Hôpital Larrey, Service de pneumologie, Toulouse, France
| | - Ari Chaouat
- Département de Pneumologie, Inserm UMR_S1116, Faculté de Médecine de Nancy, Université de Lorraine, CHRU de Nancy, Vandoeuvre-lès-Nancy, France
| | - François Picard
- Université Bordeaux, Hôpital Cardiologique du Haut-Lévêque, Heart Failure Unit and Pulmonary Hypertension Expert Centre, Bordeaux, France
| | | | - Arnaud Bourdin
- Department of Respiratory Diseases, Université Montpellier, CHU Montpellier, Montpellier, France
| | - Etienne-Marie Jutant
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Service de pneumologie, CHU Poitiers, Poitiers, France
| | - Antoine Beurnier
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Mitja Jevnikar
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Xavier Jaïs
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Gérald Simonneau
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - David Montani
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Olivier Sitbon
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Both authors contributed equally
| | - Marc Humbert
- Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France .,Department of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.,Both authors contributed equally
| |
Collapse
|
5
|
Genin V, Horeau-Langlard D, Diot E, Gagnadoux F, Lavigne C, Fournet M, Durant C, Agard C. [Characteristics of patients with connective tissue disease-associated pulmonary arterial hypertension treated with prostanoids: A multicenter retrospective study]. Rev Med Interne 2021; 42:825-831. [PMID: 34462153 DOI: 10.1016/j.revmed.2021.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 07/18/2021] [Accepted: 07/25/2021] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Pulmonary arterial hypertension (PAH) is a severe complication of connective tissue disease (CTD). Data on use of prostanoids in this particular subset of patients are lacking. We aimed to describe the characteristics of patients with PAH-CTD treated with prostanoids and the outcomes under treatment. METHODS In this multicenter retrospective study, all patients treated with prostanoids since 2006 were included. Data on PAH and CTD were collected at the time of prostanoid introduction and under treatment. RESULTS Twenty-one patients were included, of whom 20 (95%) had limited cutaneous systemic sclerosis. Nineteen patients were treated with oral monotherapy or combination before addition of prostanoid. Treprostinil was the most used molecule (57% of patients). At the time of prostanoid introduction, 90% of patients were considered at high risk for death. Among patients who had right heart catheterization during follow-up, there was no significant difference in haemodynamics. No extrarespiratory worsening of the CTD was reported. The 1-year survival under prostanoid was 62%. In univariate analysis, NYHA functional class was associated with survival under treatment. CONCLUSION This study provides original data on use of prostanoids in a cohort consisting mainly of systemic sclerosis. It underlines the difficulty to achieve a standardized assessment in this subset of patients. Safety profile was comparable with data reported in idiopathic PAH.
Collapse
Affiliation(s)
- V Genin
- Service de médecine interne, Hôtel-Dieu, CHU de Nantes, centre de compétence HTAP de l'adulte, 1, place Alexis-Ricordeau, 44000 Nantes, France.
| | - D Horeau-Langlard
- Service de pneumologie, hôpital Laennec, CHU de Nantes, centre de compétence HTAP de l'adulte, boulevard Jacques-Monod, Saint-Herblain, France
| | - E Diot
- Service de médecine interne, hôpital Bretonneau, CHRU de Tours, centre de compétence HTAP de l'adulte, 2, boulevard Tonnellé, Tours, France
| | - F Gagnadoux
- Service de pneumologie, CHU d'Angers, centre de compétence HTAP de l'adulte, 4, rue Larrey, Angers, France
| | - C Lavigne
- Service de médecine interne-immunologie clinique, CHU d'Angers, centre de compétence HTAP de l'adulte, 4, rue Larrey, Angers, France
| | - M Fournet
- Service de cardiologie, hôpital Pontchaillou, CHU de Rennes, 2, rue Henri le Guilloux, 35000 Rennes, France
| | - C Durant
- Service de médecine interne, Hôtel-Dieu, CHU de Nantes, centre de compétence HTAP de l'adulte, 1, place Alexis-Ricordeau, 44000 Nantes, France
| | - C Agard
- Service de médecine interne, Hôtel-Dieu, CHU de Nantes, centre de compétence HTAP de l'adulte, 1, place Alexis-Ricordeau, 44000 Nantes, France
| |
Collapse
|
6
|
Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, Beurnier A, Bourdin A, Bouvaist H, Bulifon S, Chabanne C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, Favrolt N, Feng Y, Horeau-Langlard D, Jevnikar M, Jutant EM, Liang Z, Magro P, Mauran P, Moceri P, Mornex JF, Palat S, Parent F, Picard F, Pichon J, Poubeau P, Prévot G, Renard S, Reynaud-Gaubert M, Riou M, Roblot P, Sanchez O, Seferian A, Tromeur C, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O. Association Between Initial Treatment Strategy and Long-term Survival in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2021; 204:842-854. [PMID: 34185620 DOI: 10.1164/rccm.202009-3698oc] [Citation(s) in RCA: 80] [Impact Index Per Article: 26.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Rationale: The relationship between initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate long-term survival in PAH according to initial treatment strategy. Methods: Retrospective analysis of incident patients with idiopathic, heritable or anorexigen-induced PAH enrolled in the French Registry (01/2006 to 12/2018). Survival was assessed according to initial strategy: monotherapy, dual or triple combination (two oral medications and a parenteral prostacyclin). Results: Among 1611 enrolled patients, 984 were initiated with monotherapy, 551 with dual and 76 with triple therapy. The triple combination group was younger with fewer comorbidities but higher mortality risk. Survival was better with triple therapy (91% at 5 years) as compared to dual or monotherapy (both 61% at 5 years), p<0.001. A propensity score matching on age, sex and pulmonary vascular resistance also showed significant differences between triple and dual therapy (10-year survival 85% vs 65%). In high-risk patients (n=243), survival was better with triple therapy vs monotherapy or dual therapy, while there was no difference between monotherapy and double therapy. In intermediate-risk patients (n=1134), survival improved with increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio 0.29, 95% confidence interval 0.11-0.80, p=0.017). Among the 148 patients initiated with a parenteral prostacyclin, those on triple therapy had better survival than those on monotherapy or dual therapy. Conclusions: Initial triple combination therapy including parenteral prostacyclin seems to be associated with better survival in PAH, particularly in the youngest high-risk patients.
Collapse
Affiliation(s)
- Athénaïs Boucly
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Laurent Savale
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Xavier Jaïs
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Fabrice Bauer
- INSERM U1096, Heart Failure Clinic and Pulmonary Hypertension Center, Service de chirurgie cardiaque, Hôpital Charles Nicole, Rouen, France
| | | | - Laurent Bertoletti
- Université de Saint-Etienne, Jean Monnet; INSERM, Thrombosis Research Group, EA3065; CIC-CIE3, Saint-Etienne, France.,Centre Hospitalier Universitaire, Service de Médecine Interne et Thérapeutique, Saint-Etienne, France
| | - Antoine Beurnier
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Physiologie, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Arnaud Bourdin
- Centre Hospitalier Regional Universitaire de Montpellier, 26905, Pneumonology, Montpellier, France
| | - Hélène Bouvaist
- CHU Grenoble Alpes Service de Cardiologie, 568151, Grenoble, France
| | - Sophie Bulifon
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Céline Chabanne
- CHU de Rennes, Hôpital Pontchaillou, Cardiology, Rennes, France
| | - Ari Chaouat
- Centre hospitalier régional universitaire de Nancy, 26920, Département de Pneumologie Hôpital de Brabois, Nancy, France.,Université de Lorraine, 137665, Inserm UMR_S 1116, Défaillance Cardiovasculaire Aigüe et Chronique, Faculté de Médecine de Nancy, Nancy, France
| | - Vincent Cottin
- Louis Pradel University Hospital, Respiratory Medicine, Lyon, France
| | - Claire Dauphin
- Hôpital Gabriel Montpied, 55448, Service de Cardiologie et Maladies Vasculaires, Clermont-Ferrand, France
| | - Bruno Degano
- Centre Hospitalier Universitaire Grenoble Alpes, 36724, Pneumologie-Physiologie, Grenoble, France
| | - Pascal De Groote
- CHR Lille - Hôpital cardiologique, Clinique de cardiologie, Lille, France
| | - Nicolas Favrolt
- CHU François Mitterrand, Service de Pneumologie et Soins Intensifs Respiratoires, Dijon, France
| | - Yuanchao Feng
- Libin Cardiovascular Institute of Alberta, 157745, Calgary, Alberta, Canada
| | | | - Mitja Jevnikar
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Etienne-Marie Jutant
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Zhiying Liang
- Libin Cardiovascular Institute of Alberta, 157745, Calgary, Alberta, Canada
| | - Pascal Magro
- CHU de Tours, service de pneumologie, Tours, France
| | - Pierre Mauran
- Paediatric and Congenital Cardiology Unit, American Memorial Hospital, CHU Reims, Reims, France
| | | | | | | | - Florence Parent
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | | | - Jérémie Pichon
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Patrice Poubeau
- CHU de La Réunion Sites Sud Saint-Pierre, 56577, Saint-Pierre, Réunion
| | | | - Sébastien Renard
- Hopital de la Timone - Deparment de Cardiologie, 375330, Marseille, France
| | | | | | - Pascal Roblot
- Department of Internal Medicine, Infectious and Tropical Diseases, Poitiers University Hospital, Poitiers, France
| | - Olivier Sanchez
- Hopital Europeen Georges Pompidou, 55647, Respiratory Unit, Paris, France
| | - Andrei Seferian
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Cécile Tromeur
- CHRU de Brest, 26990, Internal Medicine and Chest Disease, Brest, France
| | | | - Gérald Simonneau
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - David Montani
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Marc Humbert
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France
| | - Olivier Sitbon
- Centre Hospitalier Universitaire de Bicêtre, 41664, Service de Pneumologie et Soins Intensifs Respiratoires, Le Kremlin-Bicetre, France.,Paris-Saclay University Faculty of Medicine, 89691, Le Kremlin-Bicetre, France.,INSERM U999, 130034, Le Plessis Robinson, France;
| |
Collapse
|
7
|
Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, Horeau-Langlard D, Tromeur C, Chabanne C, Prevot G, Chaouat A, Moceri P, Artaud-Macari É, Degano B, Tresorier R, Boissin C, Bouvaist H, Simon AC, Riou M, Favrolt N, Palat S, Bourlier D, Magro P, Cottin V, Bergot E, Lamblin N, Jaïs X, Coilly A, Durand F, Francoz C, Conti F, Hervé P, Simonneau G, Montani D, Duclos-Vallée JC, Samuel D, Humbert M, De Groote P, Sitbon O. Corrigendum to: "Portopulmonary hypertension in the current era of pulmonary hypertension management" [J Hepatol (2020);73:130-139]. J Hepatol 2020; 73:1293-1294. [PMID: 32907706 DOI: 10.1016/j.jhep.2020.08.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Affiliation(s)
- Laurent Savale
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France; AP-HP, Service de pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France.
| | - Manuel Guimas
- Service de Pneumologie, CHRU Côte de Nacre, 14033 Caen, France
| | - Nathan Ebstein
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France; AP-HP, Service de pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Marie Fertin
- Université de Lille, Service de cardiologie, CHU Lille, Institut Pasteur de Lille, Inserm U1167, F-59000, Lille, France
| | - Mitja Jevnikar
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France; AP-HP, Service de pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - Sébastien Renard
- Département de cardiologie, Hôpital La Timone, Aix-Marseille Université, Marseille, France
| | | | - Cécile Tromeur
- European Brittany University, Brest, France; Department of Internal Medicine and Chest Diseases, University Hospital Centre La Cavale Blanche, Brest, France; Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), EA 3878, CIC INSERM 1412, Brest, France
| | - Céline Chabanne
- Département de cardiologie et maladies vasculaires, CHU de Rennes - Hôpital Pontchaillou, Rennes, France
| | - Grégoire Prevot
- CHU de Toulouse, Hôpital Larrey, Service de pneumologie, Toulouse, France
| | - Ari Chaouat
- Université de Lorraine; Département de pneumologie, CHRU de Nancy; Inserm U1116, Vandœuvre-lès-Nancy, France
| | - Pamela Moceri
- Service de cardiologie, Centre Hospitalier Universitaire de Nice-Hôpital Pasteur, Nice, France
| | | | | | - Romain Tresorier
- Service de cardiologie, Hôpital Gabriel Montpied, CHU, Clermont-Ferrand, France
| | - Clément Boissin
- Service de pneumologie, Hôpital universitaire, Montpellier, France
| | - Hélène Bouvaist
- Hôpital La Tronche, Service de cardiologie, CHU de Grenoble-Alpes, Grenoble, France
| | | | - Marianne Riou
- Service de pneumologie, nouvel hôpital civil, hôpitaux universitaires, Strasbourg, France
| | | | | | - Delphine Bourlier
- Service des maladies respiratoires, hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France
| | - Pascal Magro
- Service de pneumologie, CHRU de Tours, Tours, France
| | - Vincent Cottin
- Université Claude-Bernard Lyon 1, hôpital Louis-Pradel, service de pneumologie, Centre de référence national des maladies pulmonaires rares, UMR154, 69677 Lyon, France
| | - Emmanuel Bergot
- Service de Pneumologie, CHRU Côte de Nacre, 14033 Caen, France
| | - Nicolas Lamblin
- Université de Lille, Service de cardiologie, CHU Lille, Institut Pasteur de Lille, Inserm U1167, F-59000, Lille, France
| | - Xavier Jaïs
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France; AP-HP, Service de pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - Audrey Coilly
- AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif; UMR-S 1193, Université Paris-Saclay; DHU HEPATINOV, Villejuif, France
| | - François Durand
- Inserm, U1149, Centre de Recherche sur l'Inflammation (CRI) UMRS1149, Université de Paris, AP-HP, Service d'hépatologie, Hôpital Beaujon, Clichy, France
| | - Claire Francoz
- Inserm, U1149, Centre de Recherche sur l'Inflammation (CRI) UMRS1149, Université de Paris, AP-HP, Service d'hépatologie, Hôpital Beaujon, Clichy, France
| | - Filomena Conti
- Sorbonne Université, UPMC, Inserm, UMR_S 938 "Centre de Recherche Saint-Antoine", Paris, France; AP-HP, Pitié-Salpêtrière Hospital, Unité Médicale de Transplantation Hépatique, Paris, France
| | - Philippe Hervé
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France; AP-HP, Service de pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - Gérald Simonneau
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France; AP-HP, Service de pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - David Montani
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France; AP-HP, Service de pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - Jean-Charles Duclos-Vallée
- AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif; UMR-S 1193, Université Paris-Saclay; DHU HEPATINOV, Villejuif, France
| | - Didier Samuel
- AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif; UMR-S 1193, Université Paris-Saclay; DHU HEPATINOV, Villejuif, France
| | - Marc Humbert
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France; AP-HP, Service de pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - Pascal De Groote
- Université de Lille, Service de cardiologie, CHU Lille, Institut Pasteur de Lille, Inserm U1167, F-59000, Lille, France
| | - Olivier Sitbon
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France; AP-HP, Service de pneumologie, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| |
Collapse
|
8
|
Lavergne RA, Morio F, Danner-Boucher I, Horeau-Langlard D, David V, Hagen F, Meis JF, Le Pape P. One year prospective survey of azole resistance in Aspergillus fumigatus at a French cystic fibrosis reference centre: prevalence and mechanisms of resistance. J Antimicrob Chemother 2020; 74:1884-1889. [PMID: 31038164 DOI: 10.1093/jac/dkz144] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 02/12/2019] [Accepted: 03/08/2019] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Studies on Aspergillus fumigatus azole resistance in cystic fibrosis patients are scarce despite the fact that it is the most frequently isolated fungus from respiratory samples from these individuals. OBJECTIVES To evaluate resistance prevalence, investigate mechanisms of resistance and explore the relationship between resistant isolates by genotyping. METHODS We conducted a prospective 1 year study (from 1 January to 31 December 2015), based on the investigation of up to five colonies per sample from cystic fibrosis patients. RESULTS Twenty-three (6.5%) isolates among the 355 tested were resistant to at least one triazole drug, using the EUCAST reference method, leading to a prevalence of 6.8% (6/88 patients). Analysis of resistance mechanisms highlighted TR34/L98H (n = 10), TR46/Y121F/T289A (n = 1), WT cyp51A (n = 11) and F46Y/M172V/N248T/D255E/E427K (n = 1). No genotype was shared between patients. CONCLUSIONS This study showed a relatively stable resistance prevalence in comparison with the previous study conducted in 2010-11 (8%), although resistance mechanisms varied between the two studies.
Collapse
Affiliation(s)
- R-A Lavergne
- Parasitology and Medical Mycology Laboratory, Nantes University Hospital, Nantes, France.,Parasitology and Medical Mycology Department, Nantes University, Nantes Atlantique Universities, EA1155-IICiMed, Institut de Recherche en Santé 2, Nantes, France
| | - F Morio
- Parasitology and Medical Mycology Laboratory, Nantes University Hospital, Nantes, France.,Parasitology and Medical Mycology Department, Nantes University, Nantes Atlantique Universities, EA1155-IICiMed, Institut de Recherche en Santé 2, Nantes, France
| | - I Danner-Boucher
- Department of Pulmonology, Cystic Fibrosis Reference Centre, Nantes University Hospital, Nantes, France
| | - D Horeau-Langlard
- Department of Pulmonology, Cystic Fibrosis Reference Centre, Nantes University Hospital, Nantes, France
| | - V David
- Department of Paediatrics, Nantes University Hospital, Nantes, France
| | - F Hagen
- Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.,Department of Medical Mycology, Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands
| | - J F Meis
- Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.,Centre of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands
| | - P Le Pape
- Parasitology and Medical Mycology Laboratory, Nantes University Hospital, Nantes, France.,Parasitology and Medical Mycology Department, Nantes University, Nantes Atlantique Universities, EA1155-IICiMed, Institut de Recherche en Santé 2, Nantes, France
| |
Collapse
|
9
|
Génin V, Caristan A, Ledamany A, Horeau-Langlard D, Connault J, Durant C, Agard C. Treprostinil dans l’hypertension artérielle pulmonaire associée à la sclérodermie systémique : expérience monocentrique chez 11 patients. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Boucly A, Cottin V, Nunes H, Jaïs X, Tazi A, Prévôt G, Reynaud-Gaubert M, Dromer C, Viacroze C, Horeau-Langlard D, Pison C, Bergot E, Traclet J, Weatherald J, Simonneau G, Valeyre D, Montani D, Humbert M, Sitbon O, Savale L. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50:50/4/1700465. [DOI: 10.1183/13993003.00465-2017] [Citation(s) in RCA: 75] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 07/27/2017] [Indexed: 11/05/2022]
Abstract
Studies reporting the effects of modern strategies with pulmonary arterial hypertension (PAH)-targeted therapies in sarcoidosis-associated pulmonary hypertension (S-APH) are limited.Clinical and haemodynamic data from newly diagnosed patients with severe S-APH (mean pulmonary artery pressure (mPAP) >35 mmHg or mPAP 25–35 mmHg with cardiac index <2.5 L·min−1·m−2) were collected from the French Pulmonary Hypertension Registry between 2004 and 2015.Data from 126 patients with severe S-APH were analysed (mean±sd age 57.5±11.6 years, 74% radiological stage IV). 97 patients (77%) received PAH-targeted therapy and immunosuppressive therapy was initiated or escalated in 33 patients at the time of pulmonary hypertension diagnosis. Four months after PAH-targeted therapy initiation, mean±sd pulmonary vascular resistance decreased from 9.7±4.4 to 6.9±3.0 Wood units (p<0.001), without significant improvement in exercise capacity. Among the 11 patients treated only with immunosuppressive therapy, a haemodynamic improvement was observed in four patients, including two with compressive lymph nodes. After a median follow-up of 28 months, 39 patients needed PAH-targeted therapy escalation, nine underwent lung transplantation and 42 had died. Survival at 1, 3 and 5 years was 93%, 74% and 55%, respectively.PAH-targeted therapy improved short-term pulmonary haemodynamics in severe S-APH without change in exercise capacity. Immunosuppressive therapy improved haemodynamics in selected patients. Pulmonary hypertension in sarcoidosis remains associated with a poor prognosis.
Collapse
|
11
|
Beurnier A, Danner I, Haloun A, Tissot A, Horeau-Langlard D, Abbes S, Bry C, Magnan A, Blanc FX, Chambellan A. L’oscillométrie d’impulsion : une nouvelle façon d’évaluer la fonction respiratoire des patients adultes atteints de mucoviscidose. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Agard C, Lecomte R, Perrin F, Horeau-Langlard D. Réponse à la lettre de Montani D et al. concernant leurs commentaires sur l’article « Syndrome des anti-synthétases compliqué d’une hypertension pulmonaire : 4 observations originales » de Lecomte R. et al. Rev Med Interne 2016; 37:72-3. [DOI: 10.1016/j.revmed.2015.05.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Accepted: 05/17/2015] [Indexed: 11/24/2022]
|
13
|
Journeau L, Perrin F, Espitia O, Durant C, Lecomte R, Horeau-Langlard D, Néel A, Hamidou M, Agard C. Caractéristique des connectivites au moment où elles se compliquent d’hypertension pulmonaire précapillaire : étude monocentrique rétrospective de 42 patients diagnostiqués depuis 2003. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Lecomte R, Perrin F, Journeau L, Espitia O, Piriou N, Horeau-Langlard D, Néel A, Masseau A, Hamidou M, Agard C. [Antisynthetase syndrome with pulmonary hypertension: 4 original observations]. Rev Med Interne 2015; 36:794-9. [PMID: 25895991 DOI: 10.1016/j.revmed.2015.03.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2014] [Revised: 02/06/2015] [Accepted: 03/13/2015] [Indexed: 01/09/2023]
Abstract
INTRODUCTION Pulmonary hypertension (PH) may occur in patients with antisynthetase syndrome (ASS) but this association is poorly studied. In this article, we report 4 new cases of PH associated with ASS, and we discuss PH mechanisms in this specific disease. CASES Four patients (3 females, 1 male) with confirmed ASS associated with anti-Jo1 (n=3), anti-PL7 (n=1), and anti-Ro52 (n=3) antibodies were analyzed. They presented with subacute dyspnea in average ten years after they were first diagnosed as ASS. Diagnosis of pre-capillary PH was made (mean of mPAP: 34mmHg): PAH (n=1), group 3 PH (n=2) and PH associated to hyperthyroidism (n=1). Among three patients who received specific PAH therapy, two had significant improvement in both clinical and hemodynamic parameters. CONCLUSION During ASS, PH may occur in 5 to 10 % of cases, caused by various mechanisms. Unexplained dyspnea may be due to PH among ASS patients.
Collapse
Affiliation(s)
- R Lecomte
- Service de médecine interne, pôle hospitalo-universitaire 3, centre de compétences maladies systémiques et auto-immunes rares, hôpital Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes cedex 1, France
| | - F Perrin
- Service de médecine interne, pôle hospitalo-universitaire 3, centre de compétences maladies systémiques et auto-immunes rares, hôpital Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes cedex 1, France
| | - L Journeau
- Service de médecine interne, pôle hospitalo-universitaire 3, centre de compétences maladies systémiques et auto-immunes rares, hôpital Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes cedex 1, France
| | - O Espitia
- Service de médecine interne, pôle hospitalo-universitaire 3, centre de compétences maladies systémiques et auto-immunes rares, hôpital Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes cedex 1, France
| | - N Piriou
- Clinique cardiologique et des maladies vasculaires, pôle hospitalo-universitaire 2, hôpital Nord Laënnec, boulevard Jacques-Monod, 44093 Nantes cedex 1, France
| | - D Horeau-Langlard
- Service de pneumologie, pôle hospitalo-universitaire 2, hôpital Nord Laënnec, boulevard Jacques-Monod, 44093 Nantes cedex 1, France
| | - A Néel
- Service de médecine interne, pôle hospitalo-universitaire 3, centre de compétences maladies systémiques et auto-immunes rares, hôpital Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes cedex 1, France
| | - A Masseau
- Service de médecine interne, pôle hospitalo-universitaire 3, centre de compétences maladies systémiques et auto-immunes rares, hôpital Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes cedex 1, France
| | - M Hamidou
- Service de médecine interne, pôle hospitalo-universitaire 3, centre de compétences maladies systémiques et auto-immunes rares, hôpital Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes cedex 1, France
| | - C Agard
- Service de médecine interne, pôle hospitalo-universitaire 3, centre de compétences maladies systémiques et auto-immunes rares, hôpital Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes cedex 1, France; Inserm UMR1087, CNRS UMR6291, unité de recherche de l'institut du thorax, équipe 2 « Signalisation et hypertension artérielle », IRS université de Nantes, 8, quai Moncousu, BP70721, 44007 Nantes cedex 1, France.
| |
Collapse
|
15
|
Madjer T, Danner-Boucher I, Horeau-Langlard D, Haloun A, Lepoivre T, Sagan C, Magnan A. Severe pulmonary hypertension leading to heart-lung transplantation and revealing breast cancer. Eur Respir J 2012; 40:1057-9. [PMID: 23024331 DOI: 10.1183/09031936.00182711] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Tania Madjer
- INSERM UMR 915, Université de Nantes, CHU de Nantes, l’institut du thorax, Service de pneumologie, Plate-forme transversale d’allergologie, Centre de Réfrence National Maladies Rares Mucoviscidose, France.
| | | | | | | | | | | | | |
Collapse
|
16
|
Hérv-Arnaud G, Nowak E, Le Gall F, Rosec S, Caillon J, David V, Danner I, Dirou A, Frachon I, Haloun A, Horeau-Langlard D, Le Bihan J, Munck MR, Pelletier MP, Quiot JJ, Ramel S, Rault G, Revert K, Poulhazan E, Payan C, Le Berre R. WS20.4 Real-time PCR (RT-PCR) provides a “window of opportunity”: optimal screening of patients with cystic fibrosis (CF) through an earlier detection of Pseudomonas aeruginosa (PA). J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60144-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Grossi O, Horeau-Langlard D, Agard C, Haloun A, Lefebvre M, Neel A, Hamidou MA. Low-dose methotrexate in PAH related to T-cell large granular lymphocyte leukaemia. Eur Respir J 2012; 39:493-4. [DOI: 10.1183/09031936.00014811] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
18
|
Jonas M, Cellerin L, Sagan C, Horeau-Langlard D, Germaud P. Sténose bronchique avec dépôts ferriques. Rev Mal Respir 2006. [DOI: 10.1016/s0761-8425(06)71984-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Naudin F, Haloun A, Horeau-Langlard D, Despins P, Chailleux E. Hypertension artérielle pulmonaire sévère sous traitement par prostacycline suivi ou non d’une transplantation cardiopulmonaire : à propos de 22 cas. Rev Mal Respir 2004. [DOI: 10.1016/s0761-8425(04)71439-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Hamidou M, Haloun A, Masseau A, Horeau-Langlard D, Garand R. Hypertension artérielle pulmonaire sévère associée à une prolifération à grands lymphocytes granuleux. Efficacité du méthotrexate. Rev Med Interne 2003. [DOI: 10.1016/s0248-8663(03)80238-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|